Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults with Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results from ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority StudyEdgar T. Overton,Gary Richmond,Giuliano Rizzardini,Anders Thalme,Pierre-Marie Girard,Alexander Wong,Norma Porteiro,Susan Swindells, Jacques Reynes,Sebastian Noe,Conn Harrington,Carlos Martin Espanol,Carolina Acuipil, Asma Aksar,Yuanyuan Wang,Susan L. Ford,Herta Crauwels,Veerle van Eygen,Rodica Van Solingen-Ristea,Christine L. Latham,Shanker Thiagarajah,Ronald D'Amico,Kimberly Y. Smith,Kati Vandermeulen,William R. SpreenCLINICAL INFECTIOUS DISEASES（2023）引用 27|浏览3关键词antiretroviral therapy,cabotegravir,HIV-1,long-acting,rilpivirineAI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
